MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
Rhea-AI Summary
MacroGenics (Nasdaq: MGNX) announced that President and CEO Eric Risser will participate in a fireside chat at the Stifel 2026 Virtual Targeted Oncology Forum on May 20, 2026, at 10:30 a.m. ET.
A live webcast and 30-day replay will be available in the Investor Relations section of MacroGenics' website.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – MGNX
On the day this news was published, MGNX gained 2.16%, reflecting a moderate positive market reaction. Argus tracked a peak move of +21.7% during that session. Our momentum scanner triggered 79 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $6M to the company's valuation, bringing the market cap to $276.17M at that time. Trading volume was elevated at 2.2x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MGNX fell 1.99% while key biotech peers were mixed: ATOS down 1.34%, HLVX down 0.48%, IFRX down 4.55%, SPRO down 4.69%, and TCRX up 1.75%. The pattern suggests stock-specific trading rather than a uniform sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 11 | Asset sale agreement | Positive | +19.3% | Sale of GMP manufacturing operations to Bora for upfront cash payment. |
| May 04 | Royalty deal expansion | Positive | +2.2% | Expanded ZYNYZ royalty sale with upfront cash and milestone potential. |
| Apr 08 | Clinical hold removed | Positive | -0.3% | FDA removed partial clinical hold on Phase 2 LINNET lorigerlimab study. |
| Mar 09 | Earnings and guidance | Positive | +45.3% | 2025 results with strong revenue, cash runway into late 2027, and data milestones. |
| Feb 26 | Investor conferences | Neutral | +0.5% | Announcement of multiple March 2026 investor conference appearances and webcasts. |
Recent substantial positive reactions followed strategic monetization and earnings news, while clinical and conference updates have had muted or mixed impact.
Over recent months, MacroGenics has focused on monetizing assets and strengthening liquidity, including an agreement to sell its GMP manufacturing operations for $122.5 million and an expanded ZYNYZ royalty deal with upfront and potential milestone payments. Financial results for 2025 and early 2026 highlighted improved revenue, reduced expenses, and an extended cash runway. Clinical progress included removal of an FDA partial hold on the LINNET study. Today’s investor-forum participation continues a pattern of active investor outreach following these strategic and clinical milestones.
Market Pulse Summary
This announcement centers on MacroGenics’ participation in a targeted oncology investor forum, offering management another venue to discuss its antibody-based cancer programs and strategy. In the months leading up to this, the company reported 2025 results, extended its cash runway, and entered significant asset and royalty deals, including a planned $122.5 million manufacturing sale. Investors may watch for any new commentary on pipeline timelines, partnership economics, and capital allocation during the webcast and 30-day replay period.
Key Terms
biopharmaceutical medical
antibody-based therapeutics medical
oncology medical
webcast technical
investor relations financial
AI-generated analysis. Not financial advice.
ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the Stifel 2026 Virtual Targeted Oncology Forum on Wednesday, May 20, 2026 at 10:30 a.m. ET.
A webcast of the presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of the webcasts on its website for 30 days.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
Contacts: Jim Karrels, Senior Vice President, CFO 1-301-251-5172 info@macrogenics.com Argot Partners 1-212-600-1902 macrogenics@argotpartners.com